JAMA Network Home
Sign In
Original Investigation

Management of Exacerbations and Rescue Therapy

JAMA Neurology 10.1001/jamaneurol.2026.2558

August 10, 2026 at 11:00 AM EDT

Read the full article

In this prespecified analysis of a randomized clinical trial, inebilizumab treatment reduced exacerbation rate, including RT use, in participants with gMG who underwent a protocol-specified corticosteroid taper during MINT. These findings further support the clinical benefits of inebilizumab in AChR+ and MuSK+ gMG.

Corresponding Author: Richard J. Nowak, MD, MS, Program for Clinical and Translational Neuromuscular Research, Department of Neurology, Yale School of Medicine, Yale University, PO Box 208018, New Haven, CT 06520 (richard.nowak@yale.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.2558?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081026

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks